Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/jcpt.13183 http://scihub22266oqcxt.onion/10.1111/jcpt.13183 32779770!7405067!32779770     free     free     free       J+Clin+Pharm+Ther 2020 ; 45 (5): 1190-1193 Nephropedia Template TP {{tp|p=32779770|t=2020. QTc prolongation during antiviral therapy in two COVID-19 patients |pdf=|usr=}}{{32779770}} gab.com Text QTc prolongation during antiviral therapy in two COVID-19 patients JO: J Clin Pharm Ther http://www.kidney.de/pget.php?&tw=1&pmid=32779770 #FOAvip WHAT IS KNOWN AND OBJECTIVE: Acquired long QT syndrome secondary to drug-induced QT prolongation and torsades de pointes has been reported for antiviral drugs. However, no studies have reported an association between corrected QT (QTc) prolongation and antiviral therapy in patients with novel coronavirus disease (COVID-19). CASE DESCRIPTION: We present two cases from our institution in which patients with COVID-19 experienced QTc prolongation during treatment with antiviral therapy. Lopinavir/ritonavir, together with gender and drug-drug interactions, may have contributed to the induction of QTc prolongation in those patients. WHAT IS NEW AND CONCLUSION: Co-administration of QT-prolonging medications and drugs interfering with the metabolism of those medications must be considered in patients with COVID-19. Careful analysis of electrocardiograms for QTc duration should be performed at baseline and during antiviral therapy to identify individuals at high risk of arrhythmias. Twit Text FOAVip QTc prolongation during antiviral therapy in two COVID-19 patients ????J Clin Pharm Ther http://www.kidney.de/pget.php?&tw=1&pmid=32779770 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32779770 #FOAvip English Wikipedia <ref>{{Cite pmid|32779770}}</ref> QTc prolongation during antiviral therapy in two COVID-19 patients #MMPMID32779770 Zhu S; Wang J; Wang Y; Chu J; Liu Y; Chen X; Chen X J Clin Pharm Ther 2020[Oct]; 45 (5): 1190-1193 PMID32779770show ga WHAT IS KNOWN AND OBJECTIVE: Acquired long QT syndrome secondary to drug-induced QT prolongation and torsades de pointes has been reported for antiviral drugs. However, no studies have reported an association between corrected QT (QTc) prolongation and antiviral therapy in patients with novel coronavirus disease (COVID-19). CASE DESCRIPTION: We present two cases from our institution in which patients with COVID-19 experienced QTc prolongation during treatment with antiviral therapy. Lopinavir/ritonavir, together with gender and drug-drug interactions, may have contributed to the induction of QTc prolongation in those patients. WHAT IS NEW AND CONCLUSION: Co-administration of QT-prolonging medications and drugs interfering with the metabolism of those medications must be considered in patients with COVID-19. Careful analysis of electrocardiograms for QTc duration should be performed at baseline and during antiviral therapy to identify individuals at high risk of arrhythmias. |*COVID-19 Drug Treatment[MESH] |Antiviral Agents/administration & dosage/*adverse effects[MESH] |Drug Combinations[MESH] |Drug Interactions[MESH] |Electrocardiography[MESH] |Female[MESH] |Humans[MESH] |Long QT Syndrome/*chemically induced[MESH] |Lopinavir/administration & dosage/*adverse effects[MESH] |Middle Aged[MESH] |Ritonavir/administration & dosage/*adverse effects[MESH]QTc prolongation during antiviral therapy in two COVID-19 patients (epmc).pdf DeepDyve Pubget Overpricing